Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Immuno-Oncology Congress 2019: From the Basics of Immunotherapies to the Latest Research Results [ESMO Media Alert]

02 Dec 2019
Cancer Immunology and Immunotherapy

LUGANO, Switzerland – The ESMO Immuno-Oncology Congress 2019, the platform in Europe devoted entirely to the development and use of the immunotherapies against cancer, will take place from 11-14 December in Geneva, Switzerland, and will attract around one thousand participants from all over the world.

The event provides a comprehensive overview of this fast-moving field, from recent advances to those in the pipeline and is addressed to basic, translational and clinical researchers, immunologists, oncology clinicians.

The Congress programme features numerous thought-provoking sessions about hot topics in the field of immuno-oncology, such as:

Updated results will be presented for the following studies:

  • LBA1 - Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study
  • LBA2 - First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: safety, pharmacokinetics (PK) and immunogenicity in CASPIAN
  • LBA3 - Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 Part 2 final analysis
  • LBA4 - Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced nonsquamous NSCLC in KEYNOTE-042
  • LBA5 - KRAS mutational status and efficacy in KEYNOTE-189: pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC

Other key aspects will be dealt with and discussed by expert panellists, including:

  • Integrate Tumour Mutational Burden into daily practice, the way toward standardization
  • Use of steroids and corticosteroids in immunotherapy
  • Immunotherapy as first-line treatment across a range of tumour types
  • Combination therapy in solid tumours

Media registration

ESMO welcomes members of the press interested in reporting on cancer. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card.

Media representatives are required to observe and abide by the ESMO Media Policy
To register as press, please fill out the media registration.

Further information

ESMO Press Office


Official Congress Hashtag:  #ESMOImmuno19

Last update: 02 Dec 2019

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.